Rethinking Starting Material: Whole Blood For Autologous T-Cell Manufacture

Leukapheresis remains the established route for autologous T-cell starting material, but some workflows now require substantially fewer cells, which raises a fair question: is a large starting population always necessary? Thermo Fisher Scientific experts examine whole blood as a fit-for-purpose option, with attention to where it fits and where it does not. The discussion covers matching starting-material strategy to target cell number and downstream cell-loss tolerance, weighing collection burden against material quality and workflow duration, and managing variables such as hold time and anticoagulant choice.

Hear how the speakers work through the tradeoffs.